Main	O
Outcomes	O
and	O
Measures	O
Primary	O
outcome	O
was	O
reduction	B-PrimaryOutcome
in	I-PrimaryOutcome
lethality	I-PrimaryOutcome
by	I-PrimaryOutcome
at	I-PrimaryOutcome
least	I-PrimaryOutcome
50	I-PrimaryOutcome
%	I-PrimaryOutcome
in	O
the	O
high	O
-	O
dosage	O
group	O
compared	O
with	O
the	O
low	O
-	O
dosage	O
group	O
.	O

Data	O
presented	O
here	O
refer	O
primarily	O
to	O
safety	O
and	O
lethality	O
outcomes	O
during	O
treatment	O
on	B-TimeFrame
day	I-TimeFrame
13	I-TimeFrame
.	O

Secondary	O
end	O
points	O
included	O
participant	B-SecondaryOutcome
clinical	I-SecondaryOutcome
status	I-SecondaryOutcome
,	O
laboratory	B-SecondaryOutcome
examinations	I-SecondaryOutcome
,	O
and	O
electrocardiogram	O
results	O
.	O

Outcomes	O
will	O
be	O
presented	O
to	B-TimeFrame
day	I-TimeFrame
28	I-TimeFrame
.	O

Viral	B-OtherOutcome
respiratory	I-OtherOutcome
secretion	I-OtherOutcome
RNA	I-OtherOutcome
detection	I-OtherOutcome
was	O
performed	O
on	B-TimeFrame
days	I-TimeFrame
0	I-TimeFrame
and	I-TimeFrame
4	I-TimeFrame
.	O

Outcomes	O

Safety	O
outcomes	O
included	O
adverse	B-OtherOutcome
events	I-OtherOutcome
that	I-OtherOutcome
occurred	I-OtherOutcome
during	I-OtherOutcome
treatment	I-OtherOutcome
,	O
serious	B-OtherOutcome
adverse	I-OtherOutcome
events	I-OtherOutcome
,	O
and	O
premature	B-OtherOutcome
or	I-OtherOutcome
temporary	I-OtherOutcome
discontinuation	I-OtherOutcome
of	I-OtherOutcome
treatment	I-OtherOutcome
.	O

Adverse	O
events	O
were	O
classified	B-OutcomeDefinition
according	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
National	I-OutcomeDefinition
Cancer	I-OutcomeDefinition
Institute	I-OutcomeDefinition
Common	I-OutcomeDefinition
Terminology	I-OutcomeDefinition
Criteria	I-OutcomeDefinition
for	I-OutcomeDefinition
Adverse	I-OutcomeDefinition
Events	I-OutcomeDefinition
.	O

The	O
working	O
hypothesis	O
of	O
this	O
trial	O
was	O
that	O
the	O
lethality	O
rate	O
in	O
the	O
high	O
-	O
dosage	O
group	O
would	O
be	O
half	O
that	O
of	O
the	O
low	O
-	O
dosage	O
group	O
by	O
day	O
28	O
.	O

Thus	O
,	O
the	O
primary	O
end	O
point	O
was	O
lethality	O
by	O
day	O
28	O
.	O

Secondary	O
end	O
points	O
included	O
lethality	B-SecondaryOutcome
on	B-TimeFrame
day	I-TimeFrame
13	I-TimeFrame
,	O
participant	B-SecondaryOutcome
clinical	I-SecondaryOutcome
status	I-SecondaryOutcome
,	O
laboratory	B-SecondaryOutcome
examinations	I-SecondaryOutcome
,	O
electrocardiogram	B-SecondaryOutcome
on	B-TimeFrame
days	I-TimeFrame
13	I-TimeFrame
and	I-TimeFrame
28	I-TimeFrame
,	O
daily	B-SecondaryOutcome
clinical	I-SecondaryOutcome
status	I-SecondaryOutcome
during	I-SecondaryOutcome
hospitalization	I-SecondaryOutcome
,	O
duration	B-SecondaryOutcome
of	I-SecondaryOutcome
mechanical	I-SecondaryOutcome
ventilation	I-SecondaryOutcome
(	I-SecondaryOutcome
if	I-SecondaryOutcome
applicable	I-SecondaryOutcome
)	I-SecondaryOutcome
and	O
supplementary	B-SecondaryOutcome
oxygen	I-SecondaryOutcome
(	I-SecondaryOutcome
if	I-SecondaryOutcome
applicable	I-SecondaryOutcome
)	I-SecondaryOutcome
,	O
and	O
the	O
time	B-SecondaryOutcome
(	I-SecondaryOutcome
in	I-SecondaryOutcome
days	I-SecondaryOutcome
)	I-SecondaryOutcome
from	I-SecondaryOutcome
treatment	I-SecondaryOutcome
initiation	I-SecondaryOutcome
to	I-SecondaryOutcome
death	I-SecondaryOutcome
.	O

Here	O
we	O
present	O
analyses	O
until	O
day	O
13	O
,	O
with	O
lethality	O
as	O
the	O
primary	O
outcome	O
.	O

A	O
subgroup	O
of	O
patients	O
enrolled	O
when	O
already	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
was	O
analyzed	O
separately	O
.	O

Virologic	O
measures	O
included	O
viral	O
RNA	O
detection	O
on	O
days	O
0	O
and	O
4	O
.	O

